STAGE IVA PROSTATE CANCER AJCC V8

This study tests whether adding the drug apalutamide to usual hormone therapy and radiation can keep prostate cancer from spreading in men whose cancer reached lymph nodes after prostate removal surgery. About 586 men will be randomly assigned to get either standard treatment alo…

This study is for men with prostate cancer that has spread to other parts of the body. It compares standard drug therapy alone versus standard therapy plus either surgery to remove the prostate or radiation to the prostate. The goal is to see if adding local treatment helps patie…

This study compares a new, shorter radiation treatment (5 sessions over 2 weeks) to the standard longer treatment (20 to 45 sessions over 4 to 9 weeks) for men with high-risk prostate cancer. The goal is to see if the shorter course works just as well at preventing the cancer fro…

This study tests whether giving a drug called abemaciclib before a targeted radiation therapy (177Lu-PSMA-617) can make the radiation work better for men with advanced prostate cancer that has stopped responding to other treatments. About 30 participants will receive the combinat…

This study tests whether adding the drug talazoparib to standard hormone therapy can better control prostate cancer that still responds to hormone treatment. About 70 men with metastatic prostate cancer will receive the combination. The goal is to see if this approach lowers PSA …

This study tests whether taking high doses of vitamin D can help prevent bone loss in men aged 50 and older who are receiving hormone therapy (ADT) for prostate cancer. About 240 participants will receive either high-dose vitamin D or a placebo for one year. The goal is to see if…

This study compares two hormone therapy combinations for men with advanced prostate cancer who are also getting radiation. The goal is to see which combination causes less damage to the heart and blood vessels. Participants will be randomly assigned to receive either leuprolide o…

This study is for men with high-risk prostate cancer that hasn't spread far. It tests whether adding the drug niraparib to standard hormone therapy after radiation can better control the cancer. About 200 participants will receive either hormone therapy alone or with niraparib. T…

This study tests whether a special PET/MRI scan can accurately predict if prostate cancer has spread to nearby lymph nodes. About 50 men with high-risk prostate cancer will get the scan before surgery to remove the prostate. The goal is to see if the scan can identify who truly n…

This study tests whether adding cryoablation (freezing cancer cells) to standard radiation therapy provides better pain relief for people with cancer that has spread to the bones. About 40 adults with certain advanced cancers (like prostate, kidney, or colorectal) will be enrolle…

This study looks at why some prostate cancers become resistant to a treatment called 177Lu-PSMA, which delivers radiation directly to cancer cells. Researchers will take small tissue samples (biopsies) from tumors in 30 men with advanced prostate cancer that has spread. The goal …